Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Roche brings in RNAi capabilities through Alnylam deal' Arrowhead takes over deal

Executive Summary

Alnylam Pharmaceuticals (develops medicines that turn off disease-causing genes) has granted Roche nonexclusive rights to its RNA interference (RNAi) platform. The Big Pharma is also buying Alnylam's Kulmbach, Germany, R&D site and will convert it into a Center of Excellence focusing on RNAi therapeutics.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register